Skip to main content
Top
Published in: Obesity Surgery 3/2017

01-03-2017 | Original Contributions

Optimal Cefazolin Prophylactic Dosing for Bariatric Surgery: No Need for Higher Doses or Intraoperative Redosing

Authors: Xing Chen, Collin E. M. Brathwaite, Alexander Barkan, Keneth Hall, Gloria Chu, Patricia Cherasard, Shan Wang, David P. Nicolau, Shahidul Islam, Burke A. Cunha

Published in: Obesity Surgery | Issue 3/2017

Login to get access

Abstract

Purpose

The goal of this pharmacokinetic (PK) study was to evaluate whether a single 2-g prophylactic dose of cefazolin given (IV) bolus provides effective protective cefazolin levels for prophylaxis against methicillin-sensitive S. aureus (MSSA), the primary skin pathogen in bariatric surgery.

Materials and Methods

Thirty-seven patients having gastric bypass or sleeve gastrectomy received cefazolin 2-g preoperative prophylaxis. Serum, subcutaneous adipose tissue, and deep peri-gastric adipose tissue specimens were collected at incision and before skin closure. Cefazolin concentrations in serum and adipose tissue were determined by high-performance liquid chromatography.

Results

Penetration of cefazolin, a water soluble antibiotic, into adipose tissue was only 6–8 % of simultaneous serum levels. However, cefazolin tissue concentrations in all adipose tissue specimens, exceeded mean MIC for MSSA.

Conclusions

Prophylactic cefazolin, given as a single 2 g (IV bolus 3–5 min before skin incision) was more than adequate in providing protective cefazolin levels for the duration of bariatric surgery. Cefazolin 2 g (IV dose bolus given just before skin incision) achieves protective adipose tissue levels (> MIC of MSSA) for the duration (usually < 4 h) of bariatric surgical procedures. In this study, cefazolin 2 g (IV bolus) provided protective adipose tissue levels for 4.8 h. Since cefazolin is a water soluble antibiotic (V d = 0.2 L/Kg), penetration into adipose tissue is not V d not dose-dependent. Extremely high-dosed cefazolin, i.e., 3 or 4 g is excessive and unnecessary for bariatric surgery prophylaxis. A single cefazolin 2 g preoperative dose also eliminates the need for intraoperative redosing at 4 h.
Literature
1.
go back to reference Christou N, Jarand J, Sylvestre J, et al. Analysis of the incidence and risk factors for wound infections in open bariatric surgery. Obes Surg. 2004;14:16–2.CrossRefPubMed Christou N, Jarand J, Sylvestre J, et al. Analysis of the incidence and risk factors for wound infections in open bariatric surgery. Obes Surg. 2004;14:16–2.CrossRefPubMed
2.
go back to reference Bratzler D, Dellinger EP, Olsen K, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70:195–83.CrossRefPubMed Bratzler D, Dellinger EP, Olsen K, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70:195–83.CrossRefPubMed
3.
go back to reference Quintilliani R, Nightingale CH. Cefazolin. Ann Intern Med. 1978;89:650–6.CrossRef Quintilliani R, Nightingale CH. Cefazolin. Ann Intern Med. 1978;89:650–6.CrossRef
4.
go back to reference Grayson ML, Crow SM, McCarthy JS, et al. In: Grayson ML editor. Kucer’s the use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. (6th ed.) Hoddder Arnold: London; 2010. p. 257–74. Grayson ML, Crow SM, McCarthy JS, et al. In: Grayson ML editor. Kucer’s the use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. (6th ed.) Hoddder Arnold: London; 2010. p. 257–74.
5.
go back to reference Cunha BA, editor. Antibiotic essentials. 14th ed. New Delhi: Jaypee Brothers Medical Publishers; 2015. p. 557–9. Cunha BA, editor. Antibiotic essentials. 14th ed. New Delhi: Jaypee Brothers Medical Publishers; 2015. p. 557–9.
6.
7.
go back to reference Ho V, Nicolau D, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect. 2012;13:33–7.CrossRef Ho V, Nicolau D, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect. 2012;13:33–7.CrossRef
8.
go back to reference van Kralingen S, Taks M, Diepstraten J, et al. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol. 2011;67:985–92.CrossRefPubMed van Kralingen S, Taks M, Diepstraten J, et al. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol. 2011;67:985–92.CrossRefPubMed
9.
go back to reference Shabanzedeh DM, Sorensen LT. Laparoscopic surgery compared with open surgery decreases surgical site infection in obese patients: a systematic review and meta-analysis. Ann Surg. 2012;256:934–45.CrossRef Shabanzedeh DM, Sorensen LT. Laparoscopic surgery compared with open surgery decreases surgical site infection in obese patients: a systematic review and meta-analysis. Ann Surg. 2012;256:934–45.CrossRef
10.
go back to reference Fischer M, Dias C, Stein A, et al. Antibiotic prophylaxis in obese patients submitted to bariatric surgery. A systematic review. Acta Cir Bra. 2014;9:209–7.CrossRef Fischer M, Dias C, Stein A, et al. Antibiotic prophylaxis in obese patients submitted to bariatric surgery. A systematic review. Acta Cir Bra. 2014;9:209–7.CrossRef
Metadata
Title
Optimal Cefazolin Prophylactic Dosing for Bariatric Surgery: No Need for Higher Doses or Intraoperative Redosing
Authors
Xing Chen
Collin E. M. Brathwaite
Alexander Barkan
Keneth Hall
Gloria Chu
Patricia Cherasard
Shan Wang
David P. Nicolau
Shahidul Islam
Burke A. Cunha
Publication date
01-03-2017
Publisher
Springer US
Published in
Obesity Surgery / Issue 3/2017
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-016-2331-9

Other articles of this Issue 3/2017

Obesity Surgery 3/2017 Go to the issue